Business
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the publication of a shareholder letter from Chairman and CEO Christer Rosén marking Jupiter’s first full year as a public company an
About this update from Jupiter Neurosciences, Inc.
[{"type":"image","alt":"Jupiter Neurosciences, Inc.","displaySize":"","headline":null,"caption":"Jupiter Neurosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pYMq4mt4Y617fyJqYqyXSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6","width":300,"height":89}},"lazy":false},{"type":"text","content":"Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position","length":126,"tagName":"p"},{"type":"text","content":"Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the publication of a shareholder letter from Chairman and CEO Christer Rosén marking Jupiter’s first full year as a public company and outlining the major achievements and strategic priorities propelling the Company into 2026.","length":466,"tagName":"p"},{"type":"text","content":"Dear Fellow Shareholders,","length":25,"tagName":"p"},{"type":"text","content":"As we celebrate our first full year as a public company, I want to express my deepest gratitude for your belief in Jupiter Neurosciences and the mission we are pursuing. When we completed our IPO in December 2024, we did more than enter the public markets — we stepped into a new era defined by bold ambition, scientific conviction, and the unwavering pursuit of improving human healthspan and longevity. Over the course of 2025, Jupiter laid a powerful foundation for long-term value creation, executed on every major initiative we committed to, and opened the door to a year of extraordinary opportunity ahead.","length":612,"tagName":"p"},{"type":"text","content":"Today, we are not simply a clinical-stage biotechnology company — we are a neuroscience-driven longevity company with two powerful value creation engines, both rooted in the same breakthrough science. With the advancement of our JOTROL™ pharmaceutical platform and the commercial launch of our Nugevia consumer product line, Jupiter is entering 2026 with momentum, clarity, ...